Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

May 30, 2027
Response Due
Active
Status

Opportunity Overview

Amyotrophic Lateral Sclerosis (ALS) (also known as motor neuron disease), is caused by a loss of motor nerves or neurons. These motor nerves carry signals from the brain and spinal cord to the peripheral muscles allowing everyday movements. Loss of motor nerves in these patients leads to progressive muscle paralysis and eventual death due to failure of muscles that allow us to breath. About ~10-15% of ALS cases have a family history and specific defects, called mutations, in several genes with diverse functions are known to cause ALS. However, the processes driving motor neuron loss are poorly understood. Though the cause of ALS is unknown, many of the nerves affected in these patients show a common feature. This feature involves incorrect migration of a protein called TDP43 from within the nucleus of a cell, outside into its cytoplasm. The nucleus is the command centre of the cell and contains our DNA with specific instructions on how to make different proteins, the workhorses in a cell. The cytoplasm is the gel-like liquid within the cell that contains the nucleus and has the machinery to make proteins. Each of the nucleus and the cytoplasm have defined roles that are dependent on precise availability of specific proteins. Thus, any change in the proteins' locations will interfere with the normal activity of nerve cells resulting in their death. Relocation, also called mislocalization, of TDP43 protein from the nucleus to the cytoplasm perturbs the normal function of the nerve cells causing them to die. We have developed a new way to trigger TDP43 protein mislocalization in human nerve cells in a dish. This will allow us to look at the consequences of this relocation in detail.

With the advent of a new stem cell technology called reprogramming, skin or blood cells from patients can be converted into an embryonic state. These reprogrammed cells are called induced pluripotent stem cells (iPSC) and have the potential to be converted to any type of cell in the...

This is one of 1,831 active United Kingdom Research Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedMay 31, 2024
Procurement stageActive solicitation
Response dueMay 30, 2027
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Rotation year
Title of project: Evaluation of the quantitative accuracy and radiation dosimetry of an advanced pre-clinical multipinhole SPECT/CT theranostic imag
Discerning MCT1s role in chromatin remodelling and metabolomics changes in cancer progression
Leveraging real world data to characterise the long term impact of COVID-19
Bacterial antibiotic resistance: structure, mechanism and inhibition of ABC transporters responsible for drug efflux and cell wall biogenesis.
Characterising the role of TEX12 in centrosome and cilia development
Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2)
Iron and immunity

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.